There will always be competitors for alternate cancer treatment now and in the future due to the potential market which is why IMU has massive potential for both the solid and liquid cancer market due to the possibility of expansion to other cancer treatment. I guess they also saw the "small market" for DLBCL and somehow decided to spend the resource and fund to take the IP to commercialisation because they haven't done potential revenue calculation for this market despite the relative small diagnosis compared to other cancer????
You might be right, the commercial valuation of HER-Vaxx is questionable due to the use with chemotherapy and isn't replacing any SoC so BP aren't interested (this is same question around RAC's only IP for RC220 btw). PD1-Vaxx hasn't even started Ph2 clinical trial yet but is replacing SoC for CRC.
"Shorters spend more time researching things like this" is up there with the most stupid comment I've read on HC. The short volume for IMU has been very high ever since it entered the ASX 200 and allowed traders and shorters who look at the TA to determine their trade, biotech start-up stock will move more on FA than TA. They will need to eventually cover if everything goes as expected this year.
IMU Price at posting:
4.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)